One-Year Real-Life Data from Thai Patients with Moderate to Severe Plaque Psoriasis Treated with Secukinumab - Outcomes from the PROMPT Study. (PubMed, Dermatology) - Oct 11, 2026 - "Secukinumab demonstrated one-year retention comparable to previous real-world studies, with a favorable safety profilein Thai patients with moderate to severe plaque psoriasis. It significantly improved disease severity and HRQoL in real-world clinical settings."
Journal • Ankylosing Spondylitis • Axial Spondyloarthritis • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies
|
|
Bensachee Pattamadilok; Charoen Choonhakarn; Leena Chularojanamontri; Mati Chuamanochan; Metavee Boonsiri; Naruemon Sangob; Nisa Pretikul; Padcha Pongcharoen; Ploysyne Rattanakaemakorn; Pravit Asawanonda; Siripan Sangmala; Supapat Laodheerasiri; Warayuwadee Amornpinyo
|